ℹ️
🇨🇿
Hledání
Hledat publikace relevantní k dotazu "Aldo-keto reductase"
Aldo-keto reductase
Publikace
Předměty
Osoby
Publikace
Studium
publication
Aldo-keto reduktasy (AKR) z podrodiny AKR1C katalyzují u člověka karbonylovou redukci nového protinádorového léčiva oracinu
2007 |
Publikace bez příslušnosti k fakultě
publication
Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3
2014 |
Farmaceutická fakulta v Hradci Králové
publication
Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man
2007 |
Farmaceutická fakulta v Hradci Králové
publication
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3
2019 |
Farmaceutická fakulta v Hradci Králové
publication
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile
2018 |
Farmaceutická fakulta v Hradci Králové
publication
Diet flavonoids inhibit specific aldo-keto reductase AKR1C3
Publikace bez příslušnosti k fakultě
publication
The Role of Cytochromes P450 and Aldo-Keto Reductases in Prognosis of Breast Carcinoma Patients
2014 |
1. lékařská fakulta, 2. lékařská fakulta
publication
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism
2021 |
Farmaceutická fakulta v Hradci Králové
publication
Contribution of aldo-keto reductases to the metabolism of the novel anticancer drug oracin in man
2005 |
Farmaceutická fakulta v Hradci Králové
publication
Contribution of Aldo-Keto Reductases to the Metabolism of the Novel Anticancer Drug Oracin in Man
Publikace bez příslušnosti k fakultě
publication
Inaktivace protinádorových léčiv doxorubicinu a oracinu vlivem aldo-ketoreduktasy (AKR) 1C3
2008 |
Ústřední knihovna
publication
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3
2008 |
Farmaceutická fakulta v Hradci Králové
publication
Contribution of carbonyl reductase and aldo-keto reductase AKR1C2 to formation of C13-alcoholic metabolites of daunorubicin
Publikace bez příslušnosti k fakultě
publication
AKR1C3 Inhibitory Potency of Naturally-occurring Amaryllidaceae Alkaloids of Different Structural Types
2017 |
Farmaceutická fakulta v Hradci Králové
publication
Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment
2018 |
Farmaceutická fakulta v Hradci Králové
publication
Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters
2022 |
Farmaceutická fakulta v Hradci Králové
publication
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29
2011 |
Farmaceutická fakulta v Hradci Králové
publication
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
2022 |
Farmaceutická fakulta v Hradci Králové
publication
The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells
2009 |
Ústřední knihovna
publication
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
2009 |
Ústřední knihovna